Trials / Terminated

TerminatedNCT02716077

Early FDG PET in Melanoma

Early FDG PET/CT Imaging as a Measure of Response in Patients With Melanoma on Pembrolizumab.

Status: Terminated
Phase: N/A
Study type: Interventional
Enrollment: 6 (actual)

Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.

Conditions

Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

Interventions

Type	Name	Description
RADIATION	FDG PET/CT imaging

Timeline

Start date: 2016-03-01
Primary completion: 2021-03-01
Completion: 2021-03-01
First posted: 2016-03-23
Last updated: 2021-07-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02716077. Inclusion in this directory is not an endorsement.